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ABSTRACT 
 
Neonatal sepsis remains a global health problem due to its significant contribution to 
morbidity and mortality. The blood culture is the most reliable method for detection of 
bacterial infections. However, the sensitivity of the latter method is low and using it as a 
gold standard in diagnosis of bacteremia is fraught with difficulties.  Neutrophil CD64 
levels are upregulated in response to inflammation and tissue injury.   
 
We quantitated neutrophil CD64 by flow cytometry in neonates with signs and symptoms 
suggestive of sepsis/infection within the 1
st
 four weeks of life in a prospective 
observational study conducted at 3 hospitals in Johannesburg. Patients were classified 
into categories of infection namely definite, probable and possible according to signs and 
symptoms of infection and blood tests including blood culture results.  
 
Of 76 neonates, there was 1 infant with definite infection, 5 infants with probable, 30 
infants with possible and 32 infants with no infection. The PMN CD64 at cut off of 1.8 
had a high negative predictive value in ruling out definite (100%) or probable + definite 
infection (95.2%).  We recommend the inclusion of PMN CD64 index into the diagnostic 
algorithm for neonatal sepsis, as it has a high negative predictive value and can be used to 
rule out infection. As the positive predictive value of the test was low in confirming 
infection, PMN CD64 should be used as a screening rather than confirmatory test. 
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 1 
1. INTRODUCTION  
 
 1.1 Neonatal sepsis - a global health problem, definitions and pathophysiology 
Neonatal sepsis remains a global health problem due to its significant contribution to  
morbidity and mortality [1-2]. In developing countries neonatal sepsis is responsible 
for 30-50% of total neonatal deaths annually [3].  Infection in the neonate may be 
categorized as early onset sepsis (EOS) (<72hours of age) or late onset sepsis (LOS) 
(>72hours of age) [3-4]. 
 
 1.1.1 Definitions 
In the literature there are numerous definitions for neonatal sepsis with no universal 
agreement on one particular definition. In neonates, signs and symptoms of infection 
(implying a microbial organism as the aetiological agent) cannot be distinguished 
from signs and symptoms seen in other clinical conditions causing systemic 
inflammatory response syndrome (SIRS) [4]. The goal of the definition of sepsis by   
the International pediatric sepsis consensus conference (IPSCC) was to facilitate the 
performance of successful clinical studies in children with sepsis [5] . At the IPSCC 
twenty experts in sepsis and clinical research modified the current criteria used to 
define SIRS and sepsis in adults by incorporating pediatric physiological variables. 
Tables A1-4  ( Appendix A) define pediatric sepsis in relation to specific vital signs, 
laboratory variables and organ dysfunction [5]. Lack of evidence for bacteremia or a 
focus of infection does not exclude sepsis where there is systemic response to a 
suspected infection [6]. The negative microbiological cultures do not always exclude 
the presence of bacterial sepsis [7]. However, continuation of antimicrobial therapy 
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for suspected infection can lead to longer hospital stay and emergence of 
multiresistant organisms [7]. We hypothesize that neutrophil CD64, could be a useful 
infection marker, in differentiating between infected and non-infected groups.  
 
1.1.2 Pathophysiology 
Early onset sepsis is caused by organisms prevalent in the maternal genital tract, 
infecting the neonate transplacentally or during passage through a colonised birth 
canal at delivery [6, 8].  The micro-organisms most commonly associated with EOS 
include group B Streptococcus (GBS), Escherichia coli (E. coli), Haemophilus 
influenzae and Listeria monocytogenes. The following risk factors are associated with 
increased risk of EOS: [3, 6] 
-    Certain procedures during pregnancy such as cervical cerclage, amniocentesis and 
transcervical chorionic villus sampling 
- Low birth weight (<2500gms) or preterm baby 
- Febrile illness in the mother within 2 weeks before delivery and during delivery 
- Foul smelling and/or meconium stained amniotic fluid 
- Prolonged rupture of membranes (>24hours) 
- Prolonged and difficult delivery with instrumentation 
- Perinatal asphyxia (Apgar score of <4 at 1minute of age) or difficult resuscitation 
The LOS is acquired from the caring environment (hospital) [3, 8]. Micro-organisms 
associated with LOS include coagulase-negative Staphylococci, Staphylococcus 
aureus, E coli, Klebsiella, Pseudomonas, Enterobacter, Candida, GBS, Serratia, 
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Actinobacter, and anaerobes [8]. The risk factors implicated in LOS include the 
following: [3] 
- Neonatal Intensive Care Unit (NICU) admission 
- Poor hygiene 
- Low birth weight 
- Poor umbilical cord care 
- Prematurity 
- Bottle feeding 
- Invasive procedure 
- Superficial infection (pyoderma, umbilical cord sepsis) 
In addition to the above maternal and neonatal risk factors, there are a number of host 
factors that predispose the neonate to sepsis [8]. An immature and compromised 
immune system in the neonate, especially in premature infant, at all levels of host 
defense, including barrier function, cellular and humoral immunity contributes to 
sepsis. [1, 8-9]. 
  
 1.2 Introduction to diagnostic tools used in neonatal sepsis 
 1.2.1 Clinical signs and symptoms 
The early diagnosis of neonatal sepsis presents a clinical dilemma because of the 
variable and non-specific clinical presentation of this condition [1, 9].  
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1.2.2 Laboratory tests  
1.2.2.1 White cell count (WCC), platelet count and differential count   
Despite being widely acknowledged to lack specificity and sensitivity the white cell 
count, platelet count and white differential count are still used for the screening of 
neonates with sepsis [2, 10]. Limitations of the WCC include the following [6, 8, 10]:  
- May be normal, high or low in infection 
-  May be high due to many conditions, such as stress of delivery, following 
surgery or trauma 
- There may be differences between arterial or venous sample values 
- The differential count and assessment of the immature neutrophil cell count is 
operator dependent (subjective) and therefore not always reliable [2] 
Thrombocytopenia (low platelet count) with counts of <100,00x10^9/l (normal 
neonatal reference range in our setting for platelets is 120-450x10^9/l,  as obtained from 
Haematopathology Laboratory from Children Hospital, British Columbia, January 1990)   
may occur in neonatal sepsis but this is not specific to sepsis [8].  Increased mean platelet 
volume and platelet distribution width has been  noted  in neonates with sepsis within 2-3 
days of life [8]. 
 
1.2.2.2 Acute phase reactants 
 Acute phase reactants are also frequently used in predicting neonatal sepsis. The most 
extensively used acute phase reactant is C-reactive protein (CRP).  In a recent meta-
analysis the sensitivity of this test was estimated to be 80%, but specificity was only 60% 
- 80% [10].  Several studies agree that serial measurements of CRP guide the duration of 
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antibiotic treatment in neonates managed for suspected sepsis before the final blood 
culture results are available [6, 11-12].   
Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been shown to be useful in the 
early diagnosis of neonatal infection [12]. The latter study also suggested that the best 
prediction of neonatal sepsis was obtained from the combined use of IL-6 and CRP, that 
is IL-6 initially and CRP at 24hours. However, IL-6 is the main stimulus involved in the 
induction of the acute phase reaction and enhancement of CRP synthesis. Hence, serial 
measurement of CRP , which is much simpler to do and more cost effective,  is probably 
of more value than expensive and time consuming determination of  IL-6 plasma 
concentration in  the evaluation of neonatal sepsis [13]. 
 
One of the newer acute phase markers of infection is Procalcitonin (PCT), the 
prohormone of calcitonin, which occurs in very low concentrations in the serum of 
healthy people [14].  PCT is claimed to be more specific for bacterial infections than 
viral infections, but it is not universally accepted as an improved diagnostic assay of  
infection [15]. In the literature diagnostic accuracy of PCT appears to be superior to that 
of CRP [10]. Although PCT is reasonably predictive of neonatal sepsis, it is not 
sufficiently reliable to be used as a sole marker in evaluation of neonatal sepsis [14].  
 
1.2.2.3 Microbiological cultures 
Microbiological cultures are currently used as the gold standard for diagnosis of 
infection/sepsis and help in therapeutic decision-making, especially in choosing the 
appropriate antibiotics [2, 13, 16]. In this study the microbiological culture equals to 
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blood culture. Virological cultures were not routinely performed in our setting. The 
microbiological cultures are fraught with difficulties, which include the following: 
- There may be delay in final culture results for 48-72 hours after collection. This 
results in unnecessary exposure to antibiotics in neonates with clinical suspicion 
of sepsis and creates an environment for emergence of bacterial resistance [1, 11, 
13].  
- Genuine bacteremia may remain undetected in a significant proportion of infected 
cases because of the small volume of blood taken from preterm infants [2].  
- In neonatal sepsis blood cultures are often negative in some cases of pneumonia 
and meningitis [13]. The negative blood cultures may even occur in fatal 
generalized bacterial infection [13]. 
-  The possibility of sepsis in the presence of negative blood culture has been 
noted in neonates who had been exposed to antibiotics in utero, presumably due to 
antibiotic interference with growth of the organism in vitro [1].  
- Bacteremia may often be transient or intermittent, especially during the early 
stages of infection [2]. 
 
1.2.3 Cell surface antigens as biomarkers of infection 
Recently numerous cell surface antigens have been studied as potentially promising 
biomarkers of infection, including CD11b, CD69 and CD64 [2]. CD64 is a 72-kDa 
glycoprotein, known as FC gamma receptor 1 (FCᵧ RI), that binds immunoglobulin (Ig) 
G with high affinity [17]. CD64 is part of three major classes of leukocyte FCᵧ receptors 
including FCᵧRII (CD32) and FCᵧRIII (CD16) [10, 17]. The FC receptors, as ligands 
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for immunoglobulin constant regions, play a coordinating role in immunity and mediate 
functions such as endocytosis, phagocytosis, antibody dependent cell mediated 
cytotoxicity (ADCC), and cytokine production [18].  
 
CD64 is constitutively expressed on antigen presenting cells (monocytes, macrophages 
and dentritic cells), to a lesser extend to eosinophils, but only to a very low extent on 
resting neutrophils [10, 17-19]. Several studies have indicated that quantitation of the 
neutrophil /polymorphonuclear cell (PMN)  CD64   is a worthwhile candidate for 
evaluation as a more sensitive and specific indicator of sepsis than the other available 
diagnostics tests [15]. During neutrophil activation, under the influence of inflammatory 
cytokines (Interleukin-12, Interferon gamma-INFᵧ and Granulocyte colony stimulating 
factor-G-CSF), there is upregulation of PMN CD64 [15].  So far only one study has 
indicated that PMN CD64 has very low diagnostic sensitivity of 25.8% with high 
specificity 96.8% [13].  The majority of the studies agree that PMN CD64 has high 
diagnostic specificity and sensitivity [15, 20-22]. 
 
There are many advantages of using PMN CD64 expression as a diagnostic indicator of 
neonatal infection/sepsis, including the following: 
Upon neutrophil activation upregulation of PMN CD64 expression occurs within a 
relatively short time scale : 4-6hours for cell surface expression and 1-3 hours for 
detectable mRNA increase by Northern Blot Analysis [23]. The quantitation of PMN 
CD64 is rapid (<60minutes) and only minimal blood volume is used, which is a real 
advantage in neonates [1]. Exposure of neutrophils, in vitro and in vivo to INF-γ has been 
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shown to upregulate PMN CD64 expression resulting in enhanced antibody-mediated 
functional responses (such as phagocytosis and oxidative activity) [20, 24]. 
In contrast to other activation-related antigenic changes on neutrophils such as CD11b, 
CD18, CD16, CD45RA and CD62L, PMN CD64 expression is very low in healthy 
individuals. This makes normal ranges easy to define and independent of ethnic 
background, genetic influences or gender [23].  
PMN CD64 expression can reportedly discriminate between acute inflammatory auto-
immune disease or systemic infections where both erythrocyte sedimentation rate (ESR) 
and CRP are elevated [16].  
Bhandari et al. [1] have shown that the CD64 index has highest area under the Receiver 
Operating Characteristic curve (ROC curve), compared to commonly used 
haematological parameters (including band cells and immature/total neutrophil ratio) in 
diagnosis of neonatal sepsis. 
 
1.3 Objectives of this MMED research report  
 
In the light of above background information we prospectively evaluated the usefulness 
of PMN CD64 expression in diagnosing neonatal sepsis in our setting.  
 
1.3.1Primary Objective: 
  
Quantitation of PMN CD64 by flow cytometry in all neonates with signs and symptoms 
suggestive of sepsis/infection within the 1
st
 four weeks of life. 
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1.3.1.1 Secondary Objectives: 
 
Firstly, to assess the utility of PMN CD64 as an early marker of neonatal sepsis and   
 to compare this marker with other currently used infection markers including  CRP, 
WCC, platelet count and blood culture.  
Secondly, to assess if PMN CD64 is valuable in helping the physician to start  
  
 antibiotics early enough, and in indicating when not to start antibiotics.  
 
 
Choice of kit methodology for CD64 enumeration:  
A Leuko64 kit from Trillium Diagnostics, Liability Limited Company (LLC) has been 
selected for use in this study for the following reasons:  
The method uses a small amount of blood: only 50µL.  
 
It is quick to do, under one hour of hands on time.  
 
Reportedly has high correlation with presence of infection, with manufacturer reported 
sensitivity of 90.5%, specificity of 96.3%, positive predictive value of 95% and negative 
predictive value of 92.9% [25]. 
It is a standardized assay with internal calibrator and controls.   
 
The automated user-friendly software allows for excellent reproducibility, with 
manufacturer reported coefficient of variation of less than 5%.    
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2. MATERIALS AND METHODS 
 
2.1 Research design and site 
This prospective observational study was conducted at 3 hospitals in Johannesburg, South 
Africa, namely Rahima Moosa, Chris Hani Baragwanath and Charlotte Maxeke 
Johannesburg Academic Hospital. Consecutive neonates with suspected infection or 
sepsis were enrolled from June 2009 to July 2010. 
Permission was granted by the chief executive officers of the above mentioned hospitals 
to perform the study (see Appendix C for the permission letters). Ethical clearance was 
approved by the Human Research Ethics Committee of the University of Witwatersrand, 
Johannesburg (see Appendix D for the clearance certificate), under protocol number 
M081106. Written informed consent was granted by the parent/s of the neonates (see 
Appendix E for all informed consent forms). 
 
2.2 Inclusion criteria and study definitions 
All neonates (day 1-28) suspected of having infection/sepsis were eligible for enrollment 
in the study. Suspicion of infection included non-specific signs and symptoms such as 
respiratory distress, tachypnoea, tachycardia, hypoglycaemia, hyperglycaemia and 
maternal risk factors (please refer to Appendix B for more information).  
 
Neonates with severe congenital or chromosomal abnormalities were excluded from the 
study. The septic work up was done at the clinician’s discretion but variables (see Table 
3.1) recorded for the purposes of the study. The septic work up included the following 
tests: Full blood count (FBC), differential count (not done for every patient), CRP and 
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blood culture. The CRP in the participants of this study was done on the second day (after 
24-48 hours of suspicion of sepsis, while other tests were done on the first day of 
suspicion of sepsis). 
 
Neonates who had been on antibiotics for 48 hours or more, but clinically appeared septic 
and needed re-evaluation (another septic work up) were also included in the study.  
Categories of infection were defined using previously published criteria: [11] 
- Contamination: positive microbiological cultures with less than three signs and 
symptoms of infection and normal white cell count (WCC), differential count, 
platelets and CRP. 
- Possible infection: one or more of abnormal platelet count, WCC, differential 
count or CRP with negative microbiological cultures and less than three signs or 
symptoms of infection. 
- Probable infection: one or more of abnormal platelets, WCC, CRP, differential 
count with negative microbiological cultures with three or more signs or 
symptoms of infection.   
- Definite infection: positive microbiological cultures with any clinical signs or 
symptoms of infection and one or more of abnormal WCC, differential count, 
platelets or CRP. 
- No infection: normal CRP, WCC, differential count and platelet count with 
negative microbiological cultures and less than three symptoms or signs of 
infection. 
- Unclassified: do not fit into any of the other categories 
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In this study a differential count was not used to categorize infection as this test was not 
done in majority of the patients.  
 
2.3 Sample collection and storage: 
 
The attending paediatrician collected an additional tube of 0.3 ml peripheral blood 
(purple top with Ethylenediaminetetraacetic acid-EDTA anticoagulant) for the purposes 
of this study concurrently with the other septic work-up blood investigations. This blood 
was stored in the fridge (4
o
C) until informed consent was obtained from the parents for 
participation in the study.  In the event that the consent was refused within 48 hours, the 
blood was discarded. This method was approved by the ethics committee previously. 
As per manufacturer’s guidelines, the specimens remain acceptable for up to 24 hours 
after collection when held at room temperature (18-22
o
C) and for 48 hours when 
refrigerated (2-8ºC) [26]. 
Patients were managed by clinicians according to existing protocols. 
 
2.4 Validation 
Twenty adult blood samples were used to validate the suitability of the kit’s reference 
ranges to the local population. We evaluated the Leuko64 kit using peripheral blood 
samples from healthy adult volunteers prior to assessing the utility of this kit in neonatal 
sepsis. The reason for using adult volunteers was due to the ethical dilemma of accessing 
peripheral blood from healthy neonates. With informed consent, 3-5ml EDTA 
anticoagulated blood was drawn from 20 adult healthy volunteers (see Appendix E for 
informed consent). All participants completed a questionnaire to confirm their health 
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status (Appendix F for the questionnaire). Pregnant women were excluded from the 
study. The bloods were then processed on the Laser (LSR) II flow cytometer (Becton-
Dickinson-BD, San Jose) using the Leuko64 kit. 
Please see Appendix H for the letter requesting approval from ethics committee for 
addition of adult control group. 
 
2.5 Collation of clinical and laboratory data 
For each neonate entered in the study: 
Clinical history was retrieved from the hospital medical file, both neonatal and maternal 
(where available) and a data sheet filled (please refer to the Appendix B)  
Available laboratory results were retrieved from the laboratory information technology 
system: FBC, differential count and blood culture at the time of the septic work-up and 
CRP the next day. 
 
2.6 Neutrophil / PMN CD64 Index  
2.6.1 Contents of the kit [26] 
The CD64 kit includes three monoclonal antibodies (Reagent A): two with specificities to 
CD64 (both Fluorescein Isothiocyanate- FITC conjugated) and one recognizing CD163 
(Phycoerythrin-PE conjugated). The use of two antibodies to different epitopes of CD64 
is for two reasons. The first is to enhance the signal to noise ratio of the assay. The 
second reason is the provision of a mechanism to minimize lot to lot variation in the 
reagent fluorescence signal. The CD163, a monocyte-specific antigen, increases the 
specificity of leukocyte subpopulation identification, thus facilitating the Leuko64 
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QuantiCALC software’s cluster-finding algorithm and allowing for identification of 
internal “positive and negative” control populations. In addition the kit also contains 10x 
concentrate of red cell lysis buffer (Reagent B), as this assay is a no-wash format.  
 
A fluorescent polysterene bead suspension (Reagent C) is included for instrument 
calibration and standardization of the cellular CD64 quantitation and allows traceability 
to the National Institute of Standards and Technology (NIST) Standard Reference 
Material (SRM) 1932 (RM 8640). The microbeads serve as reference beads to properly 
adjust the sensitivities and gains of all the flow cytometer instrument fluorescence and 
light scatter signals. These beads are given an arbitary fluorescence value assignment 
within the lot-specific software of the Trillium Leuko64 kit, which is used to calibrate the 
fluorescence scales for both the FITC signal of the anti-CD64 antibodies and the PE 
signal of anti-CD163 antibody. 
 
The calculation of the PMN CD 64 performed by the lot specific Leuko64 is as follows: 
CD64 index = Bead Calibration Factor x (Mean fluorescence intensity (MFI) of PMN’s / 
MFI of Beads). The Bead Calibration Factor value is lot-specific for the Leuko64 assay 
and part of the patent. This factor allows for minimal lot to lot variations (Coeffecient of 
variation <10% among 5 lots) with the Leuko64 assay kits.  
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2.6.2 Sample and reagent preparation 
The specimens were handled according to the kit instructions as below: [26].  
The preparation of 10x Trillium Lyse (Reagent B) 1:10 dilution, was done by mixing 1 
part of the concentrated Reagent B with 9 parts of filtered distilled water. The diluted lyse 
when prepared, was stable for 1week at room temperature (20-23
o
C) or 30 days 
refrigerated (2-8
o
C). The temperature of diluted lyse must be between 20-37 
o 
C when 
used, and 1.0mL is required for each sample. 
12x75mm polysterene tubes were used for the mixing of blood and reagents. 
Initially 50 μl of Leuko64 Reagent A (Reagent A- anti-CD64 antibodies to different 
epitopes, clone22 and 32.2 and CD163 antibody) was mixed with 50μl of well mixed 
EDTA anticoagulated blood with white cell count <25 x10^9 cells/l (diluted as needed).  
The mixture was gently mixed and then  incubated for 10 minutes  in the dark room 
temperature (18-22
o
C). 
 The second step was addition of 1ml of diluted lyse (Reagent B) to the above mixture. 
The mixture was gently mixed and then  incubated for 15 minutes at room temperature. 
Intermittent vortexing before the incubations enhanced  lysis. 
The final step was addition of 5μl of Leuko64 beads (Reagent C) to the above mixture. 
The mixture was gently mixed and then analyzed on the flow cytometer. Prepared 
samples could be held at 2-8
 o
C, in the dark until analyzed (up to 6hours after 
preparation)  if not analyzed  immediately . 
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2.6.3 Flow cytometer Set-up. 
Before analyzing the samples an acquisition protocol was set up on the LSR II flow 
cytometer (Becton-Dickson, San Jose) using FACSDIVA software according to 
manufacturer instructions. 
Four 2-parameter histograms were set up:  
- Forward scatter -FS (linear) vs Side scatter-SS (log) 
- CD64 FITC vs SS (log) 
- CD163 PE vs SS (log) 
- CD163 PE vs CD64 FITC 
And 3 one-parameter histograms: 
- FL1 – CD64 FITC 
- FL2 – CD163 PE 
- FL3 (or Photomultiplier tube-PMT with filter setup able to detect 685nm). 
 
All compensation settings were turned off. 
 
A 12x75polysterene tube was prepared containing 5μl of Reagent C and 0.5ml of diluted 
Reagent B. This was used to establish PMT voltage and scatter settings. 
The above bead suspension was run to make adjustments on the one parameter 
histograms. 
The adjustments were as follows:  
- The centre of the peak on the FL1 (FITC) axis was set at the end of the second 
decade of the fluorescence intensity. The MFI= about 0.90 
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- The centre of the peak on the FL2 (PE) axis was set at ~20 (the first tic in the 
second decade of fluorescence intensity). MFI = ~0.20 
- The center of the peak on the FL3 (PerCP-Cy5-5 –A) axis was set at midscale in 
second decade. 
On the FS vs log SS histogram, the bead population was positioned at the start of the 
third decade on log side scatter signal and at channel 85-100 on forward or low angle 
scatter signal (on 256 scale use channel 20-25). 
On the cytometer the threshold to exclude platelets and red cell debris was set on log SS 
using lymphocytes. FSC 27,546 and SSC 600 
The discriminator on log SS was set to allow for collection of 50, 000 ungated events. 
Statistics were selected to report mean and median of FITC-A, PE-A and PerCP-Cy5-5-A 
channels (respectively FL1, FL2 and FL3). 
Each day, before running the samples, the bead suspension was run to set the PMT’s and  
parameter settings made so that the centre of the peak in histogram FL1 MFI was 525-
645 and the center of the peak in histogram FL3 MFI was 790-970. This standardization 
was necessary for the use of the TrilliumQuantiCALC software. 
Once the beads sample was run, the FCS files were exported at FSC 2.0 data files. 
With each new lot of Leuko64 or following instrument service, positioning of the bead 
population on the FS vs SS histogram,  the threshold to exclude platelets and red cell 
debris and confirmation of 50, 000 ungated events had to be repeated. 
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2.6.4 Listmode file analysis 
Leuko64
TM 
  QuantiCALC software (Trillium Diagnostics, LLC) was used for data 
analysis. 
This software is lot specific and protocols for use are instrument model-specific. 
Initially we used QuantiCALC Software protocol designed for BD FACS Canto 
instruments which were confirmed by the manufacture (Trillium Diagnostics, LLC) to be 
suitable for use with FACS Diva Software on the LSR II. However, with our last 
Leuko64 kit, we used QuantiCALC Software with protocol designed specifically for LSR 
II instrument.  
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See below FIGURE 2.1 and 2.2 for the examples of the result sheets for PMN CD64 
index. 
 
FIGURE 2.1: Normal PMN CD64 index result sheet, showing a monocyte positive 
control and lymphocyte negative control. 
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FIGURE 2.2 Abnormal PMN CD64 index result sheet, showing monocyte positive 
control and lymphocyte negative control. 
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2.7 Statistical analysis of the data 
Data was analysed by a statistician in the following manner: 
Stata 10.0 software was used to analyse the data from a total of 76 neonates. Normality of 
data was tested using Shapiro-Wilk test. Birth weight of participants, PMNCD64 and 
WCC showed a positively skewed distribution.  Descriptive statistics for categorical 
(proportions and percentages) and continuous variables (median) were reported. 
 
Logistic regression models were used to determine the association between selected 
neonatal factors (sex and birth weight) and infection. The logistic model considered 
infection (blood culture positive) as the outcome variable of interest and neonatal factors 
as independent factors. Logistic regression models were also used to determine the 
association between selected neonatal factors (sex, gestational age, and birth weight) and 
PMNCD64. Abnormal PMNCD64,  that is, > 1.8 [26] was considered as outcome of 
interest with the selected neonatal factors as independent variables.  
 
 ROC curves were generated for PMNCD64 at various cut offs, by plotting sensitivity 
versus 1-specificity. PMN CD64 index of >1.8, >1.6 and >2.0 were considered as 
outcome of interest.   
 
P values were reported as statistically significant if <0.05 or 5%. 
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3.  RESULTS 
 
3.1 Results of validation study 
We established that the expression of CD64 in leukocytes in the local population fell 
within the normal ranges suggested by the manufacturers (normal adult reference range 
≤1.0 PMN CD64 index; and 1-1.50 zone of diagnostic uncertainty - repeat within 12-24 
hours and clinical correlation suggested to confirm or exclude infection/sepsis) [26].  The 
mean PMN CD64 index of the samples was 0.84 (range of samples was 0.55 – 1.99), 
with a standard deviation of 0.31.  
 
19 /20 samples fell within the normal adult range of PMN CD64. We had one (1/20) 
outlier with a PMN CD64 of 1.99, suggestive of possible undiagnosed infection.  
 
Reproducibility was tested by setting up a sample from one adult volunteer ten times. The 
CV% was noted to be 2.1% for the PMN CD64 index. 
 
Statistical analysis using Spearman correlation coefficient revealed r = 0.6657 (p = 
0.0014) for neutrophils and monocytes CD64 indices, indicating a good linear relation 
between the two. Using linear regression, for every unit increase in the monocyte CD64 
index, there was increase in PMN CD64 index by 0.1347199 (R
2 
= 0.7333; p = 0.0000). 
 
Our conclusion was that, the PMN CD64 results for healthy adult volunteers were within 
the normal range as described by the Leuko64 kit, Trillium Diagnostics, LLC, and that 
monocyte CD64 and PMN CD64 are linearly related.   
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3.2 Study population  
The total number of neonates screened to be enrolled in the study was 141. Participants 
who met inclusion criteria were 76 neonates. Please refer to limitations of the study (4. 
Discussion), for further explanation as to why the rest of neonates could not be enrolled. 
Twelve mothers refused consent. 
 
3.3 Patient characteristics 
According to the clinical findings and blood culture results, patients were classified into 
the following categories of infection as defined in Section2.2.The number of the 
participants finally assigned to each category was as follows:  
definite infection (1);  
probable infection (5);  
possible infection (30);  
no infection (32);  
unclassified (5)  
contamination (0) 
 
Table 3.1 shows the demographic data in this study,  using infection classified as negative 
versus positive blood culture (that is definite infection), we found that infection was not 
statistically associated with sex, (odds ratio 1.62 ; 95% CI 0.07 – 38.61; P-0.764) or birth 
weight (odds ratio 0.99; 95% CI 0.97 – 1.01; P-0.181). 
Similarly, no other sepsis class (no infection versus definite+probable+possible 
infection); was statistically associated with sex, (odds ratio 0.83; 95% CI 0.16-4.39; P-
 24 
0.824); birth weight, (odds ratio 0.99; 95% CI 0.99- 1.00; P-0.502) and gestational age, 
(odds ratio 1.07; 95% CI 0.08-15.06; P-0.958).  
 
Using PMN CD64 index classified as normal (<1.8) versus high (>1.8), PMN CD64 was 
not statistically associated with sex, odds ratio 5.66 (95% CI 0.84 - 38.0; P-0.074); birth 
weight, odds ratio 1.00 (95% CI 0.99 - 1.00; P-0.974); and gestational age, odds ratio 
2.83 (95% CI 0.166 - 48.35; P-0.472).   
 
 The one neonate who had definite infection (positive blood culture) was female, preterm 
and had a low birth weight (890 grams). This neonate was born via the caesarean section 
route, and was four days old at the time of enrolment.  The blood culture was positive for 
gram-negative bacilli (Klebsiella pneumoniae, extended spectrum beta lactamase 
producer). Her CRP was 29.0 and PMN CD64 was index 3.70.  
The most frequent clinical sign in the study was respiratory distress 92% (70/76), 
followed by tachypnoea ~20% (15/76).  Other signs and symptoms included the 
following hypoglycaemia 6.6% (5/76); tachycardia 4.0% (3/76); hypothermia 2.6% 
(2/76); failure to wean oxygen 2.6% (2/76) and hyperglycaemia 1.3% (1/76). 
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TABLE 3.1: Demographic data  
Variable 
 
Frequency (%) 
Sex 
   Female 
 
29 (38.2) 
   Male 47 (61.8) 
Birth weight ( Range is  800-4660g, Median 1710g) 
   Less than 1000g 
 
6 (7.9) 
   Equal or greater than1000g but less than 1500g 21 (27.6) 
   Equal or greater than 1500g but less than 2500g 25 (32.9) 
   Greater than 2500g 24 (31.6) 
Mode of delivery 
   Caesarian section 
 
46 (60.5) 
   Normal vaginal 
 Delivery 
30 (39.5) 
Gestational age  
   Preterm 54 (71.0) 
   Term 22 (29.0) 
 
Demographic data of participants including sex, birth weight, mode of delivery and 
gestational age. 
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TABLE 3.2: Summary of blood results 
 
Platelets (x10^9/l) Frequency /% 
   Normal (120-450) 66 (90.4) 
   High (>450) 2 (6.9) 
   Low (<120) 5(2.7) 
  
WCC (x10^9/l)  
   Normal (9-30) 45 (60.8) 
   High (>30) 2 (2.7) 
   Low (<9) 27 (36.5) 
  
PMNCD64 index using 
cutoffs of 1.6; 1.8 or 2.0 
 
  Normal (<1.6) 38 (50) 
  High (>1.6) 38 (50) 
  
  Normal (<1.8) 42 (55.7) 
  High (>1.8) 34 (44.3) 
  
  Normal (<2.0) 46 (60.5) 
  High (>2.0) 30 (39.5) 
  
Blood Culture  
   Negative 70 (92.1) 
   Positive 1 (1.3) 
   Not done 4 (5.3) 
   Contamination 1 (1.32)* 
  
CRP (mg/L)    
   Normal 51 (75.0) 
   High 17 (25.0) 
 
Summary of the blood platelet count, white cell count, PMN CD64 index, blood culture 
and CRP. 
*This patient cultured Corynebacterium spp consistent with contamination, however, as 
patient had signs and symptoms of infection, the patient fell into the unclassified category 
of infection in Section 2.2. 
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3.4 Receiver operating characteristic (ROC) analysis 
The ROC curve is a graphical presentation of trade-off between sensitivity and 
specificity, and the greater the area under the ROC curve (AUC), the more discriminatory 
the test is[27]. AUC measures the overall ability of the test (continuous variable) to 
discriminate between individuals with and without disease.  If a test that is plotted against 
a gold standard and has AUC of 1.0 or closer to 1.0, it is a perfectly discriminatory test. 
However, if the AUC is 0.5 or less the results in terms of specificity and sensitivity are no 
better than flipping a coin (that is due to chance) [27].   
 
In our study the ROC curves were done to see if PMN CD64 is a better discriminatory 
test in comparison to the current gold standard test for diagnosing infection and sepsis 
(microbiological blood culture). In addition the performance of the PMN CD64 was also 
compared to our sepsis classifications, using them as the gold standard. Figure 3.1, 3.2 
and 3.3 shows ROC curves (using the cut-off value of 1.8 PMN CD64) in comparison to 
positive blood culture (definite infection), definite and probable (excluded possible 
infection from the all sepsis classification) and all sepsis (definite+probable+possible 
infection) respectively. The accompanying Tables 3.3; 3.; 4 and 3.5 shows the sensitivity, 
specificity, positive predictive values (PPV), negative predictive values (NPV), and 
calculations for all sepsis classifications for the cut off value of 1.8 (PMN CD64).  Table 
3.6, 3.7 and 3.8 show the summary of the sensitivity, specificity, PPV, NPV, 95% 
confidence interval (CI) and AUC values of the different cut off values (1.6; 1.8 and 2.0) 
for the PMN CD64 in different sepsis classes.   
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TABLE 3.3: PMN CD64 cut off value 1.8 plotted against definite infection 
 
 Gold standard (blood culture) 
 
Test (PMNCD64) Blood Culture 
Positive  
Blood culture 
Negative 
Total 
High 1 30 31 
Normal 0 40 40 
 1 70 71 
 
Table of CD64 results at cut off of 1.8 as a diagnostic test, using only patients with 
definite infection as gold standard positive 
 
Sensitivity: 1/1 = 100% 
 
Specificity: 40/70=57.1% 
 
PPV: 1/31=3.2% 
 
NPV: 40/40=100% 
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FIGURE 3.1: ROC curve of PMN CD64 at cut off value 1.8 versus definite infection. 
Area under the curve is 0.7857 
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TABLE 3.4: PMN CD64 at cut off value 1.8 plotted against definite+probable infection 
 
Gold standard (Sepsis) 
 
Test 
(PMNCD64) 
Sepsis 
group:definite+probable 
infection 
Positive 
Sepsis group: 
definite+probable 
infection 
Negative 
Total 
High 6 13 19 
Normal 1 20 21 
 7 33 40 
 
Table of CD64 results at cutoff of 1.8 as a diagnostic test, using patients with definite and 
probable infection as gold standard positive 
 
Sensitivity: 6/7=85.7% 
 
Specificity: 20/33=60.6 % 
 
PPV: 6/19=31.6% 
 
NPV: 20/21=95.2% 
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FIGURE 3.2: ROC curve of PMN CD64 at cut off value 1.8 versus definite+probable 
infection. Area under the curve is 0.7316 
 
TABLE 3.5: PMN CD64 cut off value 1.8 plotted against definite+probable+possible 
infection 
Gold standard (Sepsis) 
 
Test 
(PMNCD64) 
Sepsis group: 
definite+probable+possible 
Positive 
Sepsis group: 
definite+probable+possible 
Negative 
Total 
High 18 13 31 
Normal 19 20 39 
 37 33 70 
 
Table of CD64 results at cut off of 1.8 as a diagnostic test, using patients with definite, 
probable and possible infection as gold standard positive 
 
Sensitivity: 18/37=48.6% 
 
Specificity: 20/33=60.6% 
 
PPV: 18/31=58.1% 
 
NPV: 20/39=51.3% 
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FIGURE 3.3: ROC curve of PMN CD64 cut off value 1.8 versus 
definite+probable+possible infection. Area under ROC curve is 0.5463. 
 
 
Similar to above, the sensitivity, specificity, positive and negative predictive values and 
areas under the ROC curves were calculated using a cut off of 1.6 or a cut off of 2.0. The 
data is summarized below. 
 
 
TABLE 3.6: Summary of PMN CD64 index using definite infection as gold standard 
 
 1.8 cut off value 1.6 cut off value 2.0 cut off value 
Sensitivity 100% 100% 100% 
Specificity 57% 51.4% 62.9% 
PPV 3.2% 2.8% 3.7% 
NPV 100% 100% 100% 
AUC 0.7857 0.7571 0.7571 
95% CI 0.67560 – 0.87660 0.64455 – 0.85390 0.70727 – 0.89874 
 
The table shows sensitivity, specificity, positive and negative predictive values of CD64 
index at differing cut offs. Highest area under the ROC curve when patients with only 
definite infection were considered as gold standard positive was achieved using 1.8 as the 
cutoff value. 
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TABLE 3.7: Summary of PMN CD64 index using definite and probable infection as gold 
standard  
 
 1.8 cut off value 1.6 cut off value 2.0 cut off value 
Sensitivity 85.7% 85.7% 85.7% 
Specificity 60.6% 51.5% 33.3% 
PPV 31.6% 27.3% 21.4% 
NPV 95.2% 94.4% 91.6% 
AUC 0.7316 0.6861 0.7619 
95% CI 0.56800 – 0.89520 0.5154 – 0.85075 0.59983 – 0.92398 
 
The table shows sensitivity, specificity, positive and negative predictive values of CD64 
index at differing cut offs. Highest area under the ROC curve when patients with both 
definite and probable infection were considered as gold standard positive was achieved 
using 2.0 as the cutoff value. Notably, with this patient classication, the negative 
predictive value of the CD64 index was 95.2% at cutoff of 1.8 and 91.6% at cutoff of 2.0. 
 
 
 
 
 
 
 
 
TABLE 3.8: Summary of PMN CD64 index using definite, probable and possible 
infection as gold standard 
  
 1.8 cut off value 1.6 cut off value 2.0 cut off value 
Sensitivity 48.6% 51.4% 43.2% 
Specificity 60.6% 51.5% 66.7% 
PPV 58.1% 54.3% 59.3% 
NPV 51.3% 48.6% 51.2% 
AUC 0.5463 0.5143 0.5495 
95% CI 0.42867 – 0.66387 0.39534 – 0.63333 0.43459 – 0.66451 
 
The table shows sensitivity, specificity, positive and negative predictive values of CD64 
index at differing cut offs. Highest area under the ROC curve when patients with definite, 
probable and possible infection were considered as gold standard positive was achieved 
using 2.0 as the cutoff value. 
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3.5 Correlation of PMN CD64 with other markers of infection and sepsis 
There was no statistically significant correlation between the abnormal WCC, PLT and 
CRP with the high PMN CD64 index in this study. Thrombocytopenia was observed in 
7% of the neonates enrolled for the study. Thirty six percent of the participants in the 
study had a low white cell count (<9.0X10^9/l). Twenty five percent of the neonates 
enrolled in this study had a CRP of >10 mg/L (abnormal). 
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4. DISCUSSION 
 
4.1 Assessment of the utility of PMN CD64 index as early marker of infection 
 
     compared to currently used infection markers. 
 
Diagnosis of neonatal sepsis is a challenge, as there is no single reliable test for the early 
confirmation of definite sepsis [2, 11] 
Currently blood culture is the most reliable method for detection of bacterial infections. 
However, the sensitivity of this method is low and using it as a gold standard in diagnosis 
of bacteremia is fraught with difficulties [2, 28].A study done by Magudumana et al. [11] 
revealed that less than 10% of neonates they evaluated and treated for sepsis had definite 
infection. It is clear that to properly manage neonates with sepsis, a single reliable marker 
of infection is needed, to avoid unnecessary antibiotic therapy. Several published studies 
have indicated that PMN CD64 is an ideal candidate for evaluation as a more sensitive 
and specific marker of infection [1, 10, 15, 29]. 
 
In our study, after enrolling 76 participants suspected to have sepsis by clinical signs, 
only one child had a positive blood culture result. An additional 5 patients had probable 
infection, according to categories of infection classification system, and a further 30 had 
possible infection.  
 
Interpretation of the diagnostic utility of the CD64 index depends on which class of 
patients is used as the gold standard, and what is taken as the dichotomous 
“positive/negative” cut off. Using only blood culture confirmed patients as the gold 
standard positive group, the specificity and PPV were highest using 2.0 as a cut off level 
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on comparison to other cut off levels (1.6 and 1.8).  Using this cut off value (2.0), PMN 
CD64 had high sensitivity (100%) when compared to blood culture in diagnosis of 
infection. The specificity was low however with this cut off value (2.0), 62.9% and this is 
likely due to the PMN CD64 being more sensitive than the existing gold standard ( refer 
to Table 3.6) .   
 
 In neonatal sepsis a negative blood culture does not necessarily rule out infection.   
Using the patient group with both definite and probable infection as the gold standard 
positive group, PMN CD64 showed better specificity, sensitivity, PPV and NPV and 
AUC with the cut off value of 1.8 compared to other cut off values. Using this cut off,  
 the negative predictive value of PMN CD64 was  95.2%. This is the patient group we 
feel most likely represents the true positive patient group, and the high negative 
predictive value of PMN CD64 in this group indicates that PMNCD64 may find its role  
in ruling out sepsis/infection when the PMN CD64 index is within the normal reference 
range. We believe that some of this group of babies, despite negative blood cultures, had 
infection/sepsis.  As noted in literature, the reasons for the negative blood cultures are 
multiple, including possible effects of antibiotic therapy in utero [1].  
Our findings concur with the outcome of numerous studies done on the diagnostic 
performance of PMN CD64 in sepsis in view of the high sensitivity compared to blood 
culture and high negative predictive value [15, 21, 30-31]. Most studies, however, report 
high positive predictive values which do not concur with our findings. The reason for low 
positive predictive value in our study could be the fact that, as this was a prospective 
analysis, we did not start off with patients who had proven infection like the other 
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studies. As a result, we had more patients without infection, and other studies had more 
patients with infection. 
 
If the patients with possible infection are included with the definite and probable 
infection groups as the gold standard positive group (1.8 cut off), the sensitivity of PMN 
CD64 in diagnosis of infection decreases without an improvement in specificity.  The 
PPV improved from 3.2 (definite infection- sepsis group 1.8 cut off value) to 58.1%  
(definite+probable+possible –sepsis group), but the NPV dropped to 51.3 from 100%. 
We, however, feel this is not the most likely representation of the true positive patient 
group (that is infected neonates). If we hypothesize that all patients with” possible” 
infection are really in need of antibiotics for microbial sepsis, then there will be no need 
for laboratory diagnostic markers of infection. 
While our study was conducted in neonates with early onset infection ,the study done by 
Ng  et al. [9] in neonates with late onset infection showed PMN CD64 had the highest 
sensitivity and specificity at the onset of suspected infection (95 and 88 % respectively) 
and at 24hrs (97 and 90 %) [10]. In the same study PMN CD64 had best overall 
performance compared to other infection markers. 
 
 In our study there was no statistically significant correlation between PMN CD64 and 
other markers of infection (CRP, WCC and PLT). This may suggests that, CD64 is not 
giving redundant information already given by CRP, WCC and PLT, but represents an 
independent variable with additional potential clinical impact. 
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4.2 Does PMN CD64 index have a role to play in helping physicians to  
    commence or discontinue antibiotics 
We could not answer the above question in this study, as the clinical follow up was a 
challenge. However, our study has shown that the PMN CD64 may be of value in ruling 
out infection, as evidenced by NPV of 92-100%. The high NPV was noted at all the 
different cut off values; that is 1.6; 1.8 and 2.0 using ROC curves, when the gold standard 
positive groups included definite or definite + probable infection. The above findings 
support the hypothesis that if the PMN CD64 is within the normal reference range, the 
paediatrician can likely discontinue antibiotics.   
 
Current practice in the three hospitals where we conducted the study is to use serial CRP 
(at 24-48 hours), to help the paediatricians decide to stop or continue antibiotic therapy. 
In future studies, the PMN CD64 should be directly compared to serial CRP as an 
indicator of when to discontinue antibiotics. We could not directly assess the utility of 
once-off CRP as an independent predictor of sepsis, as it was one of the criteria used to 
stratify patients. 
 
One study has reported that individuals of African ancestry have increased CD64 
expression on their resting neutrophils, but this has not been confirmed [10].  In 
validation of the Leuko-64 kit using samples from healthy adult controls, we found that 
3/20 (15%) of our volunteers had PMN CD64 index higher than 1, but less than 2. These 
donors had no history to suggest infection. There could be a genetic link for slightly 
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higher PMN CD64 in some of our healthy adult volunteers. The second reason for the 
higher PMN CD64 expression could be increased exposure to infectious diseases in our 
setting (developing country). In view of the above, our normal range for PMN CD64 
expression might be slightly higher compared to first world countries. 
As suggested by the manufacture of the Leuko-64 kit we used in this study, each 
laboratory should confirm its own reference range.  
 
4.3 Limitations of the study 
 
4.3.1   Neonatal healthy controls  
 
Due to ethical dilemmas of neonatal research, we could not access healthy neonatal 
controls. Initially we received ethics clearance to use blood already taken for follow-up 
blood in neonate with no suspicion of infection but having physiological jaundice. We 
struggled to get the samples because in these neonates, paediatricians used heel prick 
sample, not venous blood. We therefore, could not use heel prick sample to determine a 
reference range for a venous sample. We used normal values as prescribed by the 
manufacture of the commercial kit. Therefore, we could not be absolutely sure if what we 
call normal was really normal for our setting 
 
The next step we took was to review the blood results on the laboratory information 
system of all neonates with no evidence of infection and retrieve their blood specimen for 
PMN CD64 quantitation. We approached the Witwatersrand University to allow us to do 
this under research and development umbrella (meaning that we did not have to ask for 
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consent from the parents).  Unfortunately with both methods we could only manage to 
get two healthy neonatal controls in a period of thirteen months.  
 
 The control from the first method had a PMN CD64 index of 1.87 (slightly higher than 
the normal reference range of <1.8.  As we failed to access age-matched controls, this 
prevented us from confirming the manufacturer  (Trillium Diagnostics, Leuko-64 kit)   
recommended neonatal reference range of PMN CD64 index  (1.8)  in our setting. 
However, as the sample population in whom the test is intended is not healthy neonates, 
but neonates with signs suggestive of infection, our control group of neonates who were 
eventually classified as “infection unlikely” is the more appropriate control group for 
evaluation of PMN CD64 as a diagnostic assay. 
 
4.3.2 Reasons why not all neonates who were screened could not be enrolled to  
       the study 
A. Consent: 
Twelve parents (either both mom and dad, or just one parent- mother or father), refused 
consent.  Some mothers we not well enough to give consent at the time of screening. 
The dilemma here was that we could only use the sample within 2 days (48hours), and if 
we did not have the consent within that time, we lost the opportunity to use that sample. 
 
B. Failure to locate the mother in within 48 hours of sample collection.  
There were multiple reasons for failure to locate the care-giver within 48 hours of sample 
collection, including the following: 
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 - Mother not at the hospital, and could not reach her telephonically  
- Mother reached telephonically or by the cell, but by the time the mother comes to  
   the hospital it was too late to use the sample. 
- The caregiver was not available with neonates referred from other hospitals or primary 
health care centers. 
 
 C. Technical: 
 In total five samples were clotted and were unsuitable for use.  
In one sample the monocyte positive control failed and another one, the lymphocyte 
negative control failed.  The reason for both failures was not found. 
 
4.3.3 Lack of follow up and clinical correlation 
 
Due to logistic concerns, and involvement of many different clinicians and confounding 
multiple variables if patients are followed up longitudinally, such as later nosocomial 
infections, follow up data and final treatment decisions were not used as outcome 
variables in this study. 
 
4.3.4 Failure to access the samples from neonates with late onset sepsis 
The objective of this study was to assess the utility of PMN CD64 in diagnosis of early 
and late onset sepsis. We failed to acquire enough samples from suspected late onset 
sepsis to assess the utility of PMNCD64 in late onset sepsis; as this depended on the 
paediatrician on duty. The latter, we believe contributed to finding only one positive 
blood culture in our study. 
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4.3.5 PMN CD64 and Human immunodeficiency virus (HIV) 
In our study we did not look a HIV status and PMN CD64. In our setting there is high 
prevalence of HIV.  The confounding effects of HIV on the CD64 index cannot be 
excluded. 
 
4.4  Strengths of the Study 
This study was a prospective study conducted in paediatric patients, in whom venous 
blood samples are difficult to access. We assessed the utility of PMN CD64 index in the 
most diagnostically relevant cohort to study – a cohort of patients with suspected sepsis. 
We analysed the PMN CD64 results in comparison with well defined categories of 
infection based on objective variables such as temperature, respiratory rate, heart rate, 
white cell count and CRP rather than subjective physician opinion to start or stop 
antibiotic therapy. 
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5. CONCLUSIONS 
 
We recommend the inclusion of PMN CD64 index into the diagnostic algorithm for 
neonatal sepsis. A negative PMN CD64 result had a high negative predictive value in 
ruling out definite (100%) or probable + definite infection (95.2%) with the 1.8 cut off 
value.  Results of PMN CD64 should be available in a much shorter time than the blood 
culture.  As the Positive predictive value of the test was low in confirming infection,  
PMN CD64 should be used as a screening rather than confirmatory test for infection. We 
believe PMN CD64 should be used in combination with other tests for infection such as 
FBC, DIFF, CRP and PCT. 
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6. APPENDICES 
APPENDIX A 
                                      
TABLE A1: PEDIATRIC AGE GROUP DEFINITIONS  
 
Newborn 0-7 days 
Neonate 7-28 days 
 
Age range definitions of the newborn and the neonate. 
Adapted from Pediatr Crit Care Med 2005 Vol. 6, No1 Page 3   
 
TABLE A2: DEFINITION OF PEDIATRIC SEPSIS 
  
SIRS – need at least 2 of the following 4 
criteria, 1 of which must be abnormal 
temperature or white cell count (WCC) 
1. Core temperature >38.5 or <36 ºC 
2. Tachycardia  >2 standard 
deviation (SD) above normal for 
age OR for children <1 year old 
bradycardia 
3. Mean respiratory rate > SD above 
normal for age or mechanical 
ventilation 
4. High or low WCC for age or 
>10% immature neutrophils 
Infection Suspected or proven (for example 
positive microbiological culture), caused 
by any pathogen or clinical syndrome 
with high probability of infection 
Sepsis SIRS in the presence of or as a result of 
suspected or proven infection 
Severe sepsis Sepsis plus one of the following: 
cardiovascular organ dysfunction, acute 
respiratory distress syndrome, or two or 
more of other organ dysfunction 
Septic shock Sepsis and cardiovascular organ 
dysfunction as defined in Table A4. 
Sepsis induced hypotension despite 
adequate fluid resuscitation (isotonic 
fluid ≥40mL/kg in 1 hr) or need for 
vasoactive drug to maintain blood 
pressure 
 
Specific definitions of pediatric sepsis continuum; including systemic inflammatory 
response syndrome (SIRS), infection, sepsis, severe sepsis and septic shock.  
Adapted from Pediatr Crit Care Med 2005 Vol. 6, No1 Page 4   
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TABLE A3: AGE-SPECIFIC VITAL SIGNS 
 
 Heart Rate,  Beats/min Respiratory 
Rate 
WCC, Systolic 
Blood  
Age group Tachycardia Bradycardia Breaths/min Leukocytes 
x 10
3
/mm
3
 
Pressure 
(BP), mm 
Hg 
0-7 days >180 <100 >50 >34 <65 
7-28 days >180 <100 >40 >19.5 or <5 <75 
 
Cut offs for abnormal vital signs for newborns and neonates. 
Adapted from Pediatr Crit Care Med 2005 Vol. 6, No1 Page 4 
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TABLE A4: ORGAN DYSFUNCTION CRITERIA 
   
Cardiovascular dysfunction, when despite 
adequate administration of isotonic 
intravenous fluid the following occur, 
that is A or B 
A: 1. Hypotension 
     2. Need for vasoactive drug to    
maintain blood pressure in normal range  
 B: Two of the following- 
1. Unexplained metabolic acidosis 
2. Increased arterial lactate 
3. Oliguria 
4. Prolonged capillary refill 
5. Core to peripheral temperature 
gap 
Respiratory – presence of one of the 
following: 
 PaO2/FIO2<300 
 PaCO2 >65 torr or 20mm Hg over 
baseline PaCO2 
 Proven need or >50% FIO2 to 
maintain saturation ≥92% 
 Need for nonelective invasive or 
non-invasive mechanical 
ventilation 
Neurologic - presence of one of the 
following: 
a. Glasgow Coma Scale (GCS) ≤11 
b. Acute change in mental status 
with decrease in GCS ≥3 points 
from abnormal baseline  
Hematologic – presence of one of the 
following: 
1. Platelet count of <80,000/mm3 or 
decline of 50% in platelet count 
from highest value recorded over 
the past 3 days 
2. International normalized ratio >2 
Renal  Serum creatinine ≥2 times upper limit of 
normal for age or 2-fold increase in 
baseline creatinine 
Hepatic – presence of the one of the 
following: 
 Total bilirubin ≥4mg/dl (NA for 
newborn) 
 Alanine transaminase 2 times 
upper limit of normal for age 
 
Criteria for organ dysfunction used to classify categories of the severity of sepsis as 
represented by Table A2. 
Adapted from Pediatr Crit Care Med 2005 Vol. 6, No1 Page 5 
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APPENDIX B  
 
TABLE B1: Data sheet 
 
Study Number    
Birth Weight   Gestation age  
Gender  Mode of delivery  
Date of SWU    
Maternal risk 
factors 
   
PROM  PPROM  
Pyrexia  Chorioamnionitis  
Foul smelling liquor  GBS carrier  
Antibiotic therapy    
Indication for SWU    
Signs of infection    
Lethargy  Abdominal 
distension 
 
Vomiting  Aspirates  
Bloody stools  Loose stools  
Respiratory distress  Increasing oxygen 
requirements 
 
Seizures  Pyrexia  
Hypothermia  Hyperglycaemia  
Hypoglycaemia  Tachypnoea 
(>60bpm) 
 
Failure to wean 
oxygen 
 Apnoea  
Tachycardia (> 160 
bpm) 
 Skin infection 
(abcess) 
 
Other (specify)    
Results    
Hb  WCC  
Platelets  Differential count  
CRP    
Blood culture    
CSF  CSF culture  
Urine   Urine culture  
Sepsis classification    
PMNCD64     
Clinical data recorded from each patient. 
SWU:  Septic work up (Full blood count, differential count, blood culture, CRP). 
CSF and urine were not always done as part of the SWU in this study. 
PMN: Polymorphonuclear cell 
PROM: Preterm rupture of membranes 
PPROM: Prolonged preterm rupture of membranes 
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APPENDIX C: 3 Letters from the three hospitals chief executives officers 
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APPENDIX D: Ethics clearance certificate 
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APPENDIX E  
Neonatal non-infection controls and Information Sheet 
 
Dear Parent/Guardian 
 
Hello, my name is Matshediso Bernice Dhlamini, a doctor in the Department of 
Molecular Medicine and Haematology at the National Health Laboratory Service, Helen 
Joseph Hospital. 
 
Together with two supervisors Prof D Ballot, a principal neonatologist at Neonatal 
Intensive Care Unit of Charlotte Maxeke Johannesburg Academic Hospital and Dr 
Tracey Wiggill, acting principal pathologist, Department of Molecular Medicine and 
Haematology, we are performing a study on newborn babies with possible infection. 
 
New babies are less able to fight infection than older children. At present it is difficult to 
prove infection in newborn babies as there is no simple reliable test to do this. The aim of 
this study is to look at a new test called Neutrophil /PMN CD64 which may help to prove 
infection as early as possible and can help show which newborn babies will need 
antibiotics.  
 
If blood needs to be taken from your baby for any other condition and your baby is free 
of infection, your baby can be included in this study as a non-infective control. We would 
like to perform the quantitation of neutrophil/PMN CD64 on the blood of your baby as 
part of our neonatal non-infection controls to validate the Leuko CD64 kit used in this 
study. A single tube of EDTA blood (0.5ml) will be taken from your baby with your 
permission. 
 
Taking part in the study is entirely up to you. If you do not want your baby to take part, 
this will not affect the care of your baby in any way. You are also free to remove your 
baby from the study at any time.  
  
If you are happy to allow your child to take part in this study as a non-infection control, 
please sign the consent form below. Please contact me if you have any queries/questions 
about the study. 
 
Thank you, Dr MB Dhlamini. 
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Informed Consent Form 
 
I hereby confirm that I have been informed by the study doctor, Matshediso Bernice 
Dhlamini and/or a medical representative, about the nature, conduct, benefits and risks of 
this study (Evaluation of neutrophil CD64 in neonatal sepsis). 
 
I has also received, read and understood the above written information regarding the 
study. I am aware that the information about the study will be anonymously processed 
into a study report. I may at any stage, without prejudice, withdraw my consent and 
participation in the study. 
 
 
I ……………………………………………………………………….  
Parent/ guardian/ caregiver of ………………………………………………………..agree 
to allow my child to participate in your study as a non-infection control . 
 
Signature: 
Date and time: 
Place: 
 
I, Dr MB Dhlamini, herewith confirm that the parent of the baby with physiological 
jaundice participating in this study has been fully informed about the nature, conduct and 
risks of the above study. 
 
Signature of the study doctor: 
Date and time: 
 
Research person/s: Dr MB Dhlamini 
Tel: 011 489 0732 / Cell 083 5785361 
Dr T Wiggill Tel: 011 489 8533 
Prof D Ballot Tel:  011 488 4232 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 53 
Volunteer healthy adult controls Information Sheet 
 
Dear Participant 
Hello, my name is Matshediso Bernice Dhlamini, a doctor in the Department of 
Molecular Medicine and Haematology at the National Health Laboratory Service, Helen 
Joseph Hospital. 
 
Together with two supervisors Prof D Ballot, a principal neonatologist at Neonatal 
Intensive Care Unit of Charlotte Maxeke Johannesburg Academic Hospital and Dr 
Tracey Wiggill, acting principal pathologist, Department of Molecular Medicine and 
Haematology, we are performing a study on newborn babies with possible infection. 
 
New babies are less able to fight infection than older children. At present it is difficult to 
prove infection in newborn babies as there is no simple reliable test to do this. The aim of 
this study is to look at a new test called Neutrophil /PMN CD64 which may help to prove 
infection as early as possible and can help show which newborn babies will need 
antibiotics.  
 
We would like to perform the quantitation of neutrophil/PMN CD64 on your blood as 
part of our adult healthy controls to validate the Leuko CD64 kit used in this study. To 
participate you need to be healthy and not currently pregnant.  A single tube of EDTA 
blood will be taken and used in the study with your consent. 
 
Please note that this study is completely anonymous and confidentially will be 
maintained. Participation in this study is voluntary. 
  
To participate you will be given a short questionnaire (to ascertain your health). 
If you are happy to participate in the study outlined above, please sign the consent form 
below. 
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Informed Consent Form 
 
I hereby confirm that I have been informed by the study doctor, Matshediso Bernice 
Dhlamini, about the nature, conduct and discomforts of this study (Evaluation of 
neutrophil CD64 in neonatal sepsis). 
 
I has also received, read and understood the above written information regarding the 
study. I am aware that the information about the study will be anonymously processed 
into a study report. I may at any stage, without prejudice, withdraw my consent and 
participation in the study. 
 
 
I ……………………………………………………………………….  
Agree to participate in your study as a healthy adult control. 
 
Signature: 
Date and time: 
Place: 
 
I, Dr MB Dhlamini, herewith confirm that the above healthy adult participating in this 
study has been fully informed about the nature, conduct and risks of the above study. 
 
Signature of the study doctor: 
Date and time: 
 
Research person/s: Dr MB Dhlamini 
Tel: 011 489 0732 / Cell 083 5785361 
Dr T Wiggill Tel: 011 489 8533 
Prof D Ballot Tel: 011 488 4232 
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APPENDIX F 
Healthy adult control Questionniare 
 
 
Age   : 
 
Sex   : 
 
Race : 
 
Are you currently healthy?   
 
 
Have you had a recent flu-like illness? 
If yes, please specify when? 
 
 
Medical history- Do you have a history of any illness? 
 
 
Current medication (including pain killers such as aspirin, panado, etc.) 
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APPENDIX K: 2 MMED individual research grants 
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